Creative Planning Acquires 665 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Creative Planning raised its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 25.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,240 shares of the company’s stock after acquiring an additional 665 shares during the quarter. Creative Planning’s holdings in Inspire Medical Systems were worth $684,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of INSP. Bank of New York Mellon Corp lifted its holdings in shares of Inspire Medical Systems by 32.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 787,815 shares of the company’s stock worth $105,433,000 after buying an additional 192,238 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Inspire Medical Systems by 51.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 459,766 shares of the company’s stock worth $98,754,000 after buying an additional 156,893 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Inspire Medical Systems by 152.7% in the 2nd quarter. AQR Capital Management LLC now owns 231,845 shares of the company’s stock worth $31,028,000 after buying an additional 140,090 shares during the period. Tri Locum Partners LP lifted its holdings in shares of Inspire Medical Systems by 465.5% in the 2nd quarter. Tri Locum Partners LP now owns 133,276 shares of the company’s stock worth $17,836,000 after buying an additional 109,710 shares during the period. Finally, Brown Capital Management LLC purchased a new stake in shares of Inspire Medical Systems in the 1st quarter worth $16,839,000. Institutional investors own 94.91% of the company’s stock.

Insider Activity

In other news, Director Shawn Mccormick sold 800 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the transaction, the director now directly owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Shawn Mccormick sold 800 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $220.00, for a total value of $176,000.00. Following the completion of the transaction, the director now directly owns 23,140 shares in the company, valued at $5,090,800. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Randy Ban sold 4,861 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $188.55, for a total transaction of $916,541.55. Following the sale, the insider now directly owns 3,056 shares in the company, valued at $576,208.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,692 shares of company stock valued at $1,099,207. Company insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

INSP has been the subject of a number of analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $260.00 price objective on shares of Inspire Medical Systems in a research note on Wednesday, August 7th. Robert W. Baird decreased their price objective on Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Truist Financial restated a “buy” rating and set a $240.00 price objective (up from $217.00) on shares of Inspire Medical Systems in a research note on Monday, September 30th. Morgan Stanley decreased their price objective on Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. Finally, KeyCorp decreased their price objective on Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $219.58.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $190.71 on Monday. The business’s 50-day moving average is $201.08 and its 200 day moving average is $180.27. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40. The firm has a market capitalization of $5.69 billion, a P/E ratio of 1,059.50 and a beta of 1.36.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.46. The business had revenue of $195.89 million for the quarter, compared to analyst estimates of $189.08 million. Inspire Medical Systems had a return on equity of 1.03% and a net margin of 0.85%. The company’s revenue was up 29.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.41) earnings per share. On average, analysts expect that Inspire Medical Systems, Inc. will post 0.75 EPS for the current year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.